SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		Washington, D.C. 20549		OMB APPROVAL					
					AFFRUVAL				
orm 4 or Form 5	t STATEN	IENT OF CHANGES IN BENEFICIAL OW	Estimated av	verage burden					
		Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 or Section 30(h) of the Investment Company Act of 1940	hours per re	sponse:					
1 0	Person [*]	2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [IGMS]	ces, Inc. [IGMS] (Check all ap Dire						
(First) SCIENCES, IN	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/18/2023		low)	Other (speci below) Officer				
EFIELD ROA	JD	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual Line)	6. Individual or Joint/Group Filing (Check Line)					
		—	X Fo	orm filed by One Rep	orting Person				
СА	94043				n One Reporting				
		Rule 10b5-1(c) Transaction Indication							
(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
	corn 4 or Form 5 continue. See ess of Reporting Lynn (First) SCIENCES, IN EFIELD ROA CA	iorm 4 of Form 5 continue. See ess of Reporting Person* Lynn (First) (Middle) SCIENCES, INC. EFIELD ROAD CA 94043	if no longer subject STATEMENT OF CHANGES IN BENEFICIAL OW Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 or Section 30(h) of the Investment Company Act of 1940 ess of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol Lynn IGM Biosciences, Inc. [IGMS] % CIENCES, INC. 3. Date of Earliest Transaction (Month/Day/Year) CA 94043 (State) (Zip)	if no longer subject form 4 or Form 5 continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 ess of Reporting Person* Lynn 2. Issuer Name and Ticker or Trading Symbol 5. Relations (Check all a Di (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. Individual Line) SCIENCES, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual Line) CA 94043 Rule 10b5-1(c) Transaction Indication	if no longer subject from 4 or Form 5 continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB ess of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [IGMS] 5. Relationship of Reporting Per (Check all applicable) Director (First) (Middle) SCIENCES, INC. 3. Date of Earliest Transaction (Month/Day/Year) 04/18/2023 6. Individual or Joint/Group Filing Line) CA 94043				

1. Title of Security (Ir	ıstr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock		04/18/2023		A		8,497(1)	Α	\$0.00	41,479	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and 7. Title and 9. Number of 3. Transaction 3A. Deemed 5. Number 8. Price of 10. Expiration Date (Month/Day/Year) Amount of Securities Derivative Conversion Date (Month/Day/Year) Execution Date, Transaction Derivative derivative Ownership if any (Month/Day/Year) Derivative or Exercise Code (Instr. Security (Instr. 5) Securities Form: Direct (D) or Indirect (I) (Instr. 4) Price of Derivative Securities Acquired Underlying Derivative Beneficially Owned 8) Security (Instr. 3 and 4) (A) or Disposed of (D) Security Following Reported Transaction(s)

(Instr. 3, 4 and 5) (Instr. 4) Amount or Number Date Expiration of ۷ Code (A) (D) Exercisable Date Title Shares Explanation of Responses:

1. These securities are restricted stock units (RSUs), granted pursuant to the election by the Reporting Person to receive RSUs in lieu of a portion of an earned cash bonus for performance in fiscal year 2022. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs shall vest in December 2023, provided that the Reporting Person remains a service provider through the vesting date.

Remarks:

1. Title of

Security

(Instr. 3)

/s/ Fred Schwarzer, by power of attorney

04/20/2023

11. Nature

of Indirect

Beneficial

Ownership (Instr. 4)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.